Aston University Investigates Weight-Loss Drugs for PCOS Treatment

Weight-loss drugs, particularly GLP-1 receptor agonists like Ozempic (semaglutide) and Mounjaro (tirzepatide), are gaining attention for their potential in managing polycystic ovary syndrome (PCOS). A new research project led by Dr Shagaf Bakour, a gynaecologist and director of medical education at Aston Medical School, has secured a £60,000 NHS research grant to investigate their use in treating this common condition. The ultimate aim is to evaluate the effect of weight-loss drugs on metabolic and reproductive outcomes in women with PCOS.

What is Polycystic Ovary Syndrome (PCOS)?

PCOS is a common condition that affects how the ovaries work, impacting up to one in ten women of reproductive age. It often leads to irregular periods, fertility challenges, and symptoms such as acne or excess hair growth due to elevated levels of male hormones (androgens). Women with PCOS are also prone to weight gain, insulin resistance, obesity, diabetes, and heightened risks of heart and circulation problems.

These metabolic issues stem from hormonal imbalances, including high insulin levels that stimulate androgen production in the ovaries. This creates a cycle of insulin resistance and ovarian dysfunction, making weight management and fertility particularly difficult. Traditional treatments focus on lifestyle changes, oral contraceptives, or metformin for insulin sensitivity, but emerging therapies like GLP-1 receptor agonists offer new hope.

GLP-1 Receptor Agonists: How They Work and Why for PCOS

GLP-1 receptor agonists, commonly known as weight-loss and blood sugar control drugs, mimic the glucagon-like peptide-1 hormone. They slow gastric emptying, reduce appetite via brain signaling, and improve insulin secretion in response to meals. Drugs such as Mounjaro (tirzepatide), a dual GLP-1/GIP agonist, and Ozempic (semaglutide), a GLP-1 agonist, have shown significant weight loss—up to 15-20% in clinical trials—and better glycemic control.

For women with PCOS, who frequently experience obesity and insulin resistance, these mechanisms align perfectly. Weight reduction can lower androgen levels, restore ovulation, and mitigate diabetes and cardiovascular risks. Preliminary evidence suggests GLP-1 agonists may improve menstrual regularity and fertility markers, though robust data specific to PCOS remains limited—precisely what this Aston University project addresses.

Comparing GLP-1 Drugs to Standard PCOS Treatments

Unlike metformin, which primarily targets insulin resistance with modest weight loss (2-5%), GLP-1 agonists deliver more substantial reductions in body weight and visceral fat. Compared to lifestyle interventions alone, they enhance adherence through pharmacological appetite suppression. However, they are not yet first-line for PCOS; this research could shift guidelines if benefits are confirmed.

The Aston University and NHS Research Project

Dr Shagaf Bakour co-developed the project with Dr Hoda Harb, a consultant obstetrician and gynaecologist at Sandwell and West Birmingham NHS Trust, who served as a co-applicant on the funded grant. Awarded through the Sandwell and West Birmingham NHS Research Fellowship scheme, the £60,000 grant supports collaborations between frontline clinicians and academic partners to enhance patient care.

The multidisciplinary team from Aston University and Sandwell and West Birmingham NHS Trust will first conduct a systematic review of existing evidence on GLP-1 receptor agonists for PCOS. This will identify knowledge gaps, prioritize patient- and clinician-relevant outcomes like fertility rates, weight loss, and cardiovascular markers, and inform the study's design.

Next Steps: Real-World Feasibility Study

Following ethical approvals, the team will integrate data from fertility services, GP records, and weight-management clinics for a real-world feasibility study. This pragmatic approach assesses how these medicines perform in everyday NHS settings, evaluating efficacy, tolerability, and potential for standardized care pathways. The goal is consistent, evidence-informed treatment to address current variations in PCOS management.

Expert Insights from the Research Leads

"The aim is to give women with PCOS evidence-informed, clearer treatment options and more consistent care. The project hopes to show whether these medicines can improve both general health and fertility health, while also helping local services develop clearer care pathways. Currently, care can vary, and women do not always get the same advice or treatment options. The research could lead to earlier support, better long-term health, and more joined-up care for a condition that affects many women but is still often overlooked.

"In the longer term, the work is intended to produce published evidence, support further external funding, and help prevent longer-term health problems linked to PCOS."

— Dr Shagaf Bakour

"The effects of PCOS, which include infertility, are very emotive subjects and so we are delighted to support Dr Shagaf Bakour and Dr Hoda Harb with their research into possible treatments.

"We should be doing all we can within research and development to advance healthcare for women and to better help future generations with this condition."

— Professor Elizabeth Hughes, Director of Research and Development at Sandwell and West Birmingham NHS Trust

Safety Considerations and Side Effects of GLP-1 Drugs in PCOS

While promising, GLP-1 receptor agonists carry risks like nausea, vomiting, diarrhea, and rare pancreatitis or gallbladder issues. In PCOS patients, monitoring thyroid function and kidney health is crucial, especially with diabetes comorbidity. Long-term data on fertility impacts is emerging, but no increased birth defect risks have been noted in users who conceive. Women considering these should discuss with their gynaecologist, weighing benefits against gastrointestinal tolerance.

What This Means for Patients with PCOS

Who Might Benefit?

Women with PCOS and obesity, insulin resistance, or fertility struggles could see improvements in metabolic health, menstrual cycles, and conception chances. This study emphasizes real-world application, potentially leading to NHS-integrated protocols.

Practical Guidance

• Consult your doctor before starting GLP-1 drugs; they're prescription-only.
• Combine with diet and exercise for optimal results.
• Track symptoms like periods, weight, and side effects—apps like Shotlee can assist in logging these for better doctor discussions.
• Monitor blood sugar and hormones regularly.

Key Takeaways

• A £60,000 NHS grant funds Aston University's investigation of GLP-1 drugs like Ozempic and Mounjaro for PCOS.
• The study reviews evidence and tests real-world feasibility for metabolic and reproductive benefits.
• Aims to standardize care, reduce health risks, and improve fertility outcomes.
• PCOS affects 1 in 10 reproductive-age women; GLP-1s target core issues like obesity and insulin resistance.

Conclusion: A Step Toward Better PCOS Care

This Aston University project represents a pivotal step in bridging evidence gaps for GLP-1 receptor agonists in PCOS management. By focusing on patient-centered outcomes, it promises clearer pathways, earlier interventions, and published data to guide future treatments. Women with PCOS should stay informed and discuss these options with healthcare providers for personalized care.